A notable example is the development and clinical application of siRNA-based drugs such as patisiran (Onpattro) and vutrisiran (Amvuttra) for the treatment of hereditary transthyretin-mediated amyloidosis [53]. This evidence concerns the gene TTR and amyloidosis.